|
ATC-Code*
|
Wirkstoff
|
Bemerkung
|
|
A07A
|
Intestinale Antiinfektiva
|
|
|
A09AA02
|
Multienzyme (Lipase, Protease etc.)
|
|
|
A10A
|
Insuline und Analoga
|
|
|
A11CC05
|
Colecalciferol (Vitamin D3)
|
parenterale Formen
|
|
A11DA01
|
Thiamin (Vitamin B1)
|
parenterale Formen
|
|
A11DB
|
Vitamin B1 in Kombination mit Vitamin B6 und/oder Vitamin B12
|
parenterale Formen
|
|
A11GA01
|
Ascorbinsäure (Vitamin C)
|
parenterale Formen
|
|
A11HA02
|
Pyridoxin (Vitamin B6)
|
parenterale Formen
|
|
A11HA04
|
Riboflavin (Vitamin B2)
|
parenterale Formen
|
|
A12CC02
|
Magnesiumsulfat
|
parenterale Formen
|
|
A12CE02
|
Natriumselenit
|
parenterale Formen
|
|
B01AA04
|
Phenprocoumon
|
|
|
B01AA07
|
Acenocoumarol
|
|
|
B01AB01
|
Heparin
|
> 100 IE/mL
|
|
B01AB02
|
Antithrombin III
|
|
|
B01AB04
|
Dalteparin
|
|
|
B01AB05
|
Enoxaparin
|
|
|
B01AB06
|
Nadroparin
|
|
|
B01AB09
|
Danaparoid
|
|
|
B01AD02
|
Alteplase
|
Dosierung > 2 mg
|
|
B01AD04
|
Urokinase
|
|
|
B01AD11
|
Tenecteplase
|
|
|
B01AE03
|
Argatroban
|
|
|
B01AE07
|
Dabigatran
|
|
|
B01AF01
|
Rivaroxaban
|
|
|
B01AF02
|
Apixaban
|
|
|
B01AF03
|
Edoxaban
|
|
|
B01AX05
|
Fondaparinux
|
|
|
B02AA02
|
Tranexamsäure
|
parenterale Formen
|
|
B02BD
|
Blutgerinnungsfaktoren
|
|
|
B05AA01
|
Albumin
|
|
|
B05BA01
|
Aminosäuren
|
parenterale Formen
|
|
B05BA02
|
Fettemulsionen
|
parenterale Formen
|
|
B05BA03
|
Kohlenhydrate
|
parenterale Formen mit Glukose Konzentration ≥ 20 % w/V, Volumen > 50 ml
|
|
B05BA10
|
Lösungen zur parenteralen Ernährung, Kombinationen
|
zentralvenös formulierte 3-Kammerbeutelsysteme
|
|
B05BB01
|
Elektrolytlösungen
|
|
|
B05DB
|
Hypertone Lösungen zur Peritonealdialyse
|
|
|
B05XA14
|
Dinatrium-1-glycerinphosphat
|
parenterale Formen
|
|
B05XA31
|
Elektrolyte, Kombinationen, inkl. reine Spurenelemente
|
parenterale Formen
|
|
B05XB02
|
Alanyl-glutamin
|
parenterale Formen
|
|
B05XC
|
Vitamine
|
parenterale Formen
|
|
B05ZB
|
Hämofiltrate
|
|
|
C01CA02
|
Isoprenalin
|
|
|
C01CA03
|
Noradrenalin
|
|
|
C01CA07
|
Dobutamin
|
|
|
C01CA24
|
Adrenalin
|
|
|
C03CA01
|
Furosemid
|
parenterale Formen
|
|
C07AB02
|
Metoprolol
|
parenterale Formen
|
|
C07AG01
|
Labetalol
|
|
|
D08AC52
|
Chlorhexidin, Kombinationen
|
Volumen > 100 mL
|
|
D08AG02
|
Iod-Povidon
|
Volumen > 100 mL
|
|
D08AJ57
|
Octenidin, Kombinationen
|
|
|
D08AX05
|
Isopropanol
|
|
|
D08AX53
|
Propanol, Kombinationen
|
|
|
G02AD05
|
Sulproston
|
|
|
H01AA02
|
Tetracosactid
|
|
|
H01BA02
|
Desmopressin
|
parenterale Formen
|
|
H01BB02
|
Oxytocin
|
parenterale Formen
|
|
H01BB03
|
Carbetocin
|
|
|
J01
|
Antibiotika zur systemischen Anwendung
|
ohne J01Z
|
|
J02
|
Antimykotika zur systemischen Anwendung
|
|
|
J04A
|
Mittel zur Behandlung der Tuberkulose
|
|
|
J05AB06
|
Ganciclovir
|
|
|
J05AB14
|
Valganciclovir
|
|
|
J05AD01
|
Foscarnet
|
|
|
J05AH02
|
Oseltamivir
|
|
|
J06BA01
|
Humane Immunglobuline
|
unspezifisch, extravaskulär
|
|
J06BA02
|
Humane Immunglobuline
|
unspezifisch, intravaskulär
|
|
J06BB01
|
Anti-D-Immunglobulin
|
|
|
J06BB02
|
Tetanus-Immunglobulin
|
|
|
J06BB03
|
Varizella/Zoster Immunglobulin
|
|
|
J06BB04
|
Hepatitis B-Immunglobulin
|
|
|
J06BB05
|
Tollwut-Immunglobulin
|
|
|
J07
|
Impfstoffe
|
|
|
L01AA01
|
Cyclophosphamid
|
|
|
L01AA03
|
Melphalan
|
|
|
L01AA06
|
Ifosfamid
|
|
|
L01AA09
|
Bendamustin
|
|
|
L01AB01
|
Busulfan
|
|
|
L01AC01
|
Thiotepa
|
|
|
L01AD01
|
Carmustin
|
|
|
L01AX03
|
Temozolomid
|
|
|
L01AX04
|
Dacarbazin
|
|
|
L01BA01
|
Methotrexat
|
parenterale Formen
|
|
L01BB02
|
Mercaptopurin
|
|
|
L01BB03
|
Tioguanin
|
|
|
L01BB04
|
Cladribin
|
parenterale Formen
|
|
L01BB05
|
Fludarabin
|
|
|
L01BB07
|
Nelarabin
|
|
|
L01BC01
|
Cytarabin
|
|
|
L01BC02
|
Fluorouracil
|
|
|
L01BC05
|
Gemcitabin
|
|
|
L01BC06
|
Capecitabin
|
|
|
L01BC07
|
Azacitidin
|
|
|
L01CA02
|
Vincristin
|
|
|
L01CA04
|
Vinorelbin
|
|
|
L01CB01
|
Etoposid
|
|
|
L01CD01
|
Paclitaxel
|
|
|
L01CD02
|
Docetaxel
|
|
|
L01CD04
|
Cabazitaxel
|
|
|
L01CE02
|
Irinotecan
|
Alter ATC-Code
|
|
L01CX01
|
Trabectedin
|
|
|
L01DB01
|
Doxorubicin
|
|
|
L01DB03
|
Epirubicin
|
|
|
L01DC01
|
Bleomycin
|
|
|
L01EA01
|
Imatinib
|
|
|
L01EB04
|
Osimertinib
|
|
|
L01EC02
|
Dabrafenib
|
|
|
L01EE01
|
Trametinib
|
|
|
L01EH02
|
Neratinib
|
|
|
L01EL01
|
Ibrutinib
|
|
|
L01EX04
|
Vandetanib
|
|
|
L01EX10
|
Midostaurin
|
|
|
L01FA01
|
Rituximab
|
|
|
L01FB01
|
Inotuzumab ozogamicin
|
|
|
L01FC01
|
Daratumumab
|
|
|
L01FD01
|
Trastuzumab
|
|
|
L01FD02
|
Pertuzumab
|
|
|
L01FD03
|
Trastuzumab emtansin
|
|
|
L01FE01
|
Cetuximab
|
|
|
L01FF02
|
Pembrolizumab
|
|
|
L01FF03
|
Durvalumab
|
|
|
L01FF05
|
Atezolizumab
|
|
|
L01FG01
|
Bevacizumab
|
|
|
L01FG02
|
Ramucirumab
|
|
|
L01FX02
|
Gemtuzumab ozogamicin
|
|
|
L01FX04
|
Ipilimumab
|
|
|
L01FX05
|
Brentuximab vedotin
|
|
|
L01FX07
|
Blinatumomab
|
|
|
L01XA01
|
Cisplatin
|
|
|
L01XA02
|
Carboplatin
|
|
|
L01XA03
|
Oxaliplatin
|
|
|
L01XF01
|
Tretinoin
|
|
|
L01XG01
|
Bortezomib
|
|
|
L01XG02
|
Carfilzomib
|
|
|
L01XH03
|
Panobinostat
|
|
|
L01XJ01
|
Vismodegib
|
|
|
L01XX05
|
Hydroxycarbamid
|
|
|
L01XX23
|
Mitotan
|
|
|
L01XX24
|
Pegaspargase
|
|
|
L01XX27
|
Arsentrioxid
|
|
|
L01XX52
|
Venetoclax
|
|
|
L02AE03
|
Goserelin
|
|
|
L02BA01
|
Tamoxifen
|
|
|
L02BA03
|
Fulvestrant
|
|
|
L03AX03
|
BCG Impfstoff
|
|
|
L04AA04
|
Antithymocytäres Immunglobulin (Kaninchen)
|
|
|
L04AA13
|
Leflunomid
|
|
|
L04AB06
|
Golimumab
|
|
|
L04AC02
|
Basiliximab
|
|
|
L04AX01
|
Azathioprin
|
perorale Formen
|
|
L04AX03
|
Methotrexat
|
perorale Formen
|
|
L04AX04
|
Lenalidomid
|
|
|
M01AB05
|
Diclofenac
|
parenterale Formen
|
|
M01AB15
|
Ketorolac
|
parenterale Formen
|
|
M01AE17
|
Dexketoprofen
|
parenterale Formen
|
|
M03AB01
|
Suxamethonium
|
|
|
M03AC04
|
Atracurium
|
|
|
M03AC09
|
Rocuronium
|
|
|
M03AC11
|
Cisatracurium
|
|
|
M03CA01
|
Dantrolen
|
|
|
N01AB07
|
Desfluran
|
|
|
N01AF03
|
Thiopental
|
|
|
N01AH
|
Opioidanästhetika
|
parenterale Formen
|
|
N01AH06
|
Remifentanil
|
|
|
N01AX03
|
Ketamin
|
|
|
N01AX10
|
Propofol
|
|
|
N01BB02
|
Lidocain
|
parenterale Formen
|
|
N01BB03
|
Mepivacain
|
|
|
N01BB04
|
Prilocain
|
|
|
N02AA01
|
Morphin
|
|
|
N02AA03
|
Hydromorphon
|
|
|
N02AA05
|
Oxycodon
|
|
|
N02AA08
|
Dihydrocodein
|
exkl. Antitussiva
|
|
N02AA55
|
Oxycodon und Naloxon
|
|
|
N02AB02
|
Pethidin
|
|
|
N02AB03
|
Fentanyl
|
|
|
N02AE01
|
Buprenorphin
|
|
|
N02AF02
|
Nalbuphin
|
|
|
N02AJ06
|
Codein und Paracetamol Kombination
|
|
|
N02AJ13
|
Tramadol und Paracetamol Kombination
|
|
|
N02AX01
|
Tilidin
|
|
|
N02AX02
|
Tramadol
|
|
|
N02AX06
|
Tapentadol
|
|
|
N02BA01
|
Acetylsalicylsäure, inkl. Lysinacetylsalicylat
|
parenterale Formen
|
|
N02BB02
|
Metamizol, Natriumsalz
|
parenterale Formen
|
|
N02BE01
|
Paracetamol
|
parenterale Formen
|
|
N03AX18
|
Lacosamid
|
|
|
N05BA01
|
Diazepam
|
parenterale Formen und Tropfen
|
|
N05BA06
|
Lorazepam
|
parenterale Formen
|
|
N07BC02
|
Methadon
|
|
|
N07BC05
|
Levomethadon
|
|
|
R03CC02
|
Salbutamol
|
parenterale Formen
|
|
R03CC05
|
Hexoprenalin
|
|
|
S01AD03
|
Aciclovir
|
Augensalbe
|
|
S01JA01
|
Fluorescein
|
Augentropfen
|
|
V03AB14
|
Protamin
|
|
|
V03AB35
|
Sugammadex
|
|
|
V03AE02
|
Sevelamer
|
|
|
V03AE03
|
Lanthan III-carbonat
|
|
|
V03AE05
|
Eisen(III)-oxidhydroxid Saccharose-Stärke-Komplex
|
|
|
V03AE07
|
Calciumacetat
|
|
|
V03AF03
|
Calciumfolinat (Folinsäure)
|
|
|
V08AA
|
Wasserlösliche nephrotrope hochosmolare Röntgenkontrastmittel
|
|
|
V08AB
|
Wasserlösliche nephrotrope niederosmolare Röntgenkontrastmittel
|
|
|
V08BA
|
Bariumhaltige Röntgenkontrastmittel
|
|
|
V08CA
|
Paramagnetische Kontrastmittel
|
|
|
V08DA
|
Ultraschallkontrastmittel
|
|
- *
- Der ATC-Code (Code des Wirkstoffs im «Anatomical Therapeutic Chemical Classification System») kann in der offiziellen englischen Fassung auf der Website des «Collaborating Centre for Drug Statistics Methodology» der Weltgesundheitsorganisation (WHO) unter folgender Adresse abgerufen werden:
www.whocc.no
> ATC/DDD Index. Die Zuteilung der Produkte folgt der ATC-Einteilung des Schweizerischen Heilmittelinstituts.
|